About this trial
Inclusion (J0):
* Information * Verification of inclusion and non-inclusion criteria * Collection of consent * MRI examination with injection of contrast product as part of the treatment comprising the sequences:
T1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1 injected FABIR iso without injection (added as part of care in case of suspected ASH or meningitis) FLAIR 1.0 without injection (added as part of care for suspected ASH or meningitis) T2 BFFE XD (added by search) FABIR iso injected (added by research) 3D PD T1 0.55 MSDE iso injected (added by research)
Clinical information (SRM on inclusion, on discharge and at 3 months and recurrence within the year) will be collected from the patient's medical file
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients over 18 years of age
suspicion of pathology likely to be associated with narrowing or obstruction of one or more venous sinuses (cerebral thrombophlebitis, tissue damage with venous extension, idiopathic HIC
venous narrowing or obstruction proven by one of the above pathologies, requiring as part of routine care an injected MRI (search for impact, monitoring, pre-therapeutic assessment or prognosis)
Express consent to participate in the study
Disqualifiers
Absolute contraindication to MRI
Patient benefiting from a legal protection measure
Pregnant or breastfeeding woman
Trial population
Patient presenting for imaging as part of their treatment
Trial design
Cohort
Prospective
Treatments tested in this trial
MRI sequences
Other interventionperform additional sequences added by research
Treatment groups
Trial outcomes
Primary outcomes
Using a new MRI sequence for the detection of lymph nods
Inversion recovery pulse sequences in MRI will be used to detect lymph nods.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.